Introduction:The outbreak of new coronavirus has become a global public health challenge. Given a consequential liver function, and the high risk of death coming from liver disorders, the assessment of Novel Coronavirus Disease on liver function is importance. Hence, we carried out this meta-analysis to heightening insight into the occult features of COVID 19, which is likely to affect liver function. Method:This study was performed using databases of Web of Science, Scopus, and PubMed. We considered English cross-sectional and case-series papers, which reported available findings on the association between liver injury and COVID-19 infection. We used the STATA v.11 and random effect model for data analysis. Result:In this present meta-analysis, 52 papers, including 8,463 COVID-19 patients, were studied. The prevalence of increased liver enzymes among the patients, including Alanine aminotransferase, Aspartate aminotransferase, were 30% and 21% in non-severe patients, respectively, which were 38% and 48% in severe patients. The prevalence of increasing C-reactive protein, Lactate dehydrogenase, D-dimer, and Bilirubin were 55%, 39%, 28%, and 10% in non-severe patients respectively, which were 78%, 75%, 79% and 17% in sever patients.The prevalence of liver toxicity as a complication of COVID-19 was 20%.Also patients who have severe condition are 5.54, 4.22, 4.96, 4.13 and 4.34 times more likely to have elevated CRP, ALT, AST, LDH, D-dimer enzymes retrospectively. Conclusion:Elevation of some liver markers were higher in patients with severe COVID-19 infection. All to gather, we assumed that abnormal liver markers could act as a prognostic factor for a better survey of COVID-19.

中文翻译：

---

新型冠状病毒疾病（COVID-19）的肝功能：系统评价和荟萃分析

简介：新的冠状病毒的爆发已成为全球公共卫生的挑战。考虑到相应的肝功能，以及因肝病而导致死亡的高风险，评估新型冠状病毒疾病对肝功能的重要性。因此，我们进行了这项荟萃分析，以加深对COVID 19隐匿特征的认识，这很可能会影响肝功能。方法：本研究是使用Web of Science，Scopus和PubMed的数据库进行的。我们考虑了英文横断面和案例系列论文，这些论文报告了关于肝损伤与COVID-19感染之间关联的现有发现。我们使用STATA v.11和随机效应模型进行数据分析。结果：在本荟萃分析中，研究了52篇论文，包括8,463例COVID-19患者。非重症患者中肝酶升高的患病率分别为30％和21％，其中丙氨酸转氨酶，天冬氨酸转氨酶分别为重度患者的38％和48％。非严重患者中C反应蛋白，乳酸脱氢酶，D-二聚体和胆红素升高的发生率分别为55％，39％，28％和10％，分别为78％，75％，79％和17。重度患者中肝毒性作为COVID-19并发症的患病率为20％，重症患者的CRP，ALT，AST，LDH升高的可能性也高出5.54、4.22、4.96、4.13和4.34倍，D-二聚酶的回顾性研究。结论：重症COVID-19感染患者某些肝脏标志物的升高较高。大家聚集